The impact of stigma on medication adherence in patients with functional dyspepsia

Abstract

Background Psychological factors contribute to the pathogenesis of functional dyspepsia (FD). Antidepressant agents are beneficial in treatment of refractory FD. However, their efficacy is greatly hindered by the poor treatment adherence. Stigma is present in patients with chronic diseases or mental disorders and could affect adherence. The present study was aimed to evaluate stigma prevalence in FD patients and to explore the impact of stigma on treatment adherence to antidepressants. Methods Functional dyspepsia patients unsatisfied with the regular first‐line treatment and received newly initiated antidepressant medicine were recruited and subjected to antidepressant treatment for 8 weeks. Stigma scales and symptom scores of dyspepsia, depression, and anxiety were analyzed before and after treatment. Associations between stigma and medication adherence were evaluated. Key results One hundred and ten of the enrolled 138 participants reported minimal disease‐related internalized stigma, and 28 reported mild stigma before antidepressant therapy. Male gender, lower education, and higher scores of dyspepsia, depression, and anxiety were predictors of stigma before treatment. The mean stigma scores increased after 8‐week antidepressant treatment. A proportion (36.4%‐89.9%) of patients showed stigma attached to antidepressant therapy in the 4‐question survey. Post‐treatment stigma scores negatively correlated with treatment adherence and efficacy. Patients with decreased post‐treatment stigma scores displayed better medication adherence and symptom improvement compared to those with elevated or unaltered post‐treatment stigma scores. Conclusions Patients with refractory FD report stigma attached to the disease and antidepressants. It is an obstacle to treatment adherence and efficacy of antidepressant medication in FD therapy.

Deconstructing stigma as a barrier to treating DGBI: Lessons for clinicians

“…In their study, 25 the authors prospectively evaluated 138 refractory FD patients, 18–70 years old, seen in the clinic with mild to moderate anxiety or depression. Those who did not achieve a 50% reduction in symptoms when initially treated with anti‐secretory or prokinetic therapies were prescribed by a psychiatrist and gastroenterologist 8 weeks of a neuromodulator medication.…”

Understanding racial disparities in the care of patients with irritable bowel syndrome: The need for a unified approach

“…Interestingly, a study in functional dyspepsia, a DBGI, by Yan et al showed some people who received treatment with antidepressants developed stigma associated with their medications. 57 Bias is another factor which can have an impact on healthcare outcomes. Studies have shown that clinicians tend to view patients with IBS negatively.…”

Improving Clinician-Patient Communication Alleviates Stigma in Patients With Functional Dyspepsia Receiving Antidepressant Treatment

“…However, compliance with antidepressant treatment is handicapped due to stigma. 10 - 13 Our recent research found that stigma associated with FD and antidepressant medications could interfere with treatment adherence. 10 A large proportion of FD patients refuse to take antidepressants and report concerns such as “my family says these drugs are for insane people” or “these drugs will make me lose my mind.” These are typical expressions of stigma.…”